Free Trial
→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad)

ArriVent BioPharma 8/14/2024 Earnings Report

ArriVent BioPharma logo
$29.12 -0.44 (-1.49%)
(As of 12/3/2024 ET)

ArriVent BioPharma EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.65
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

ArriVent BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ArriVent BioPharma Announcement Details

Quarter
Date
8/14/2024
Time
After Market Closes

Conference Call Resources

Powered by Quartr
Coins Set to Soar with a Pro-Crypto White House (Ad)

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

ArriVent BioPharma Earnings Headlines

ArriVent BioPharma Advances Cancer Therapeutics Pipeline
November 19, 2024 | markets.businessinsider.com
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results
November 16, 2024 | msn.com
Lock in this disruptor’s share price before 12/5
Spencer Rascoff co-founded Zillow. Austin Allison sold his company to Zillow for $125M. Now they’ve joined forces to launch a venture transforming the $1.3T vacation home market – and the results are already turning heads. This company is leading the co-ownership revolution, offering buyers a chance to own a fraction of a luxury vacation home instead of the entire thing. It’s a model that’s unlocked new demand and earned them over $100M in gross profits in four years.
December 4, 2024 | Pacaso (Ad)
ArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy Rating
November 16, 2024 | markets.businessinsider.com
ArriVent BioPharma, Inc. Buy Rating: Strong Financials, Clinical Progress, and Promising Catalysts Support Upside Potential
November 16, 2024 | markets.businessinsider.com
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
November 14, 2024 | markets.businessinsider.com
See More ArriVent BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ArriVent BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ArriVent BioPharma and other key companies, straight to your email.

About ArriVent BioPharma

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

View ArriVent BioPharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles